{"doi":"10.1007\/s00210-009-0441-9","coreId":"195795","oai":"oai:lra.le.ac.uk:2381\/7909","identifiers":["oai:lra.le.ac.uk:2381\/7909","10.1007\/s00210-009-0441-9"],"title":"Desensitisation of native and recombinant human urotensin-II receptors.","authors":["Batuwangala, M. S.","Calo, G.","Guerrini, R.","Ng, L. L.","McDonald, J.","Lambert, D. G."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2009-08-13","abstract":"Full text of this item is not currently available on the LRA.Human urotensin-II (U-II) is an 11-amino-acid cyclic peptide that activates a Gq-coupled receptor named UT. Little is known about the desensitisation profile of this receptor as peptide binding is essentially irreversible. In the present study, we have examined the effects of U-II and carbachol on Ca2+ signalling in SJCRH30 rhabdomyosarcoma (receptor density, Bmax ~0.1 pmol\/mg protein) and human embroynic kidney (HEK)hUT (B max ~1.4 pmol\/mg protein) cells expressing native and recombinant UT, respectively. In SJCRH30, HEKhUT and human peripheral blood mononuclear cells induced to express native UT by treatment with 2 \u03bcg\/ml lipopolysaccharide (LPS), we have measured the effects of U-II treatment on UT mRNA. In SJCRH30 cells, primary stimulation with carbachol (250 \u03bcM) did not affect a secondary challenge with U-II (1 \u03bcM) and primary challenge with U-II did not affect a secondary challenge with carbachol. In contrast, in HEKhUT cells, primary stimulation with carbachol (250 \u03bcM) reduced a secondary challenge to U-II (1 \u03bcM) by 84% and primary challenge with U-II reduced a secondary challenge to carbachol by 76%. Pre-treatment of SJCRH30 cells with U-II reduced UT mRNA after 6 h and this returned to basal after 24 h. In recombinant HEKhUT cells, UT mRNA expression increased following a 6 h treatment with 1 \u03bcM U-II. U-II treatment of na\u00efve un-stimulated peripheral blood mononuclear cells was without effect. However, when UT expression is up-regulated following 15 h of LPS treatment, a 6 h U-II challenge reduced UT mRNA by 66%. In summary, we report differences in the desensitisation profiles of native and recombinant U-II receptors. Design and interpretation of functional experiments are hampered by irreversibility of U-II binding","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Springer Verlag","rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:lra.le.ac.uk:2381\/7909<\/identifier><datestamp>\n                2015-12-07T12:14:01Z<\/datestamp><setSpec>\n                com_2381_10<\/setSpec><setSpec>\n                com_2381_9550<\/setSpec><setSpec>\n                col_2381_11<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nDesensitisation of native and recombinant human urotensin-II receptors.<\/dc:title><dc:creator>\nBatuwangala, M. S.<\/dc:creator><dc:creator>\nCalo, G.<\/dc:creator><dc:creator>\nGuerrini, R.<\/dc:creator><dc:creator>\nNg, L. L.<\/dc:creator><dc:creator>\nMcDonald, J.<\/dc:creator><dc:creator>\nLambert, D. G.<\/dc:creator><dc:subject>\nCalcium<\/dc:subject><dc:subject>\nDesensitisation<\/dc:subject><dc:subject>\nPeripheral blood mononuclear cells<\/dc:subject><dc:subject>\nPolymerase chain reaction<\/dc:subject><dc:subject>\nUrotensin II<\/dc:subject><dc:subject>\nUrotensin II receptor<\/dc:subject><dc:description>\nFull text of this item is not currently available on the LRA.<\/dc:description><dc:description>\nHuman urotensin-II (U-II) is an 11-amino-acid cyclic peptide that activates a Gq-coupled receptor named UT. Little is known about the desensitisation profile of this receptor as peptide binding is essentially irreversible. In the present study, we have examined the effects of U-II and carbachol on Ca2+ signalling in SJCRH30 rhabdomyosarcoma (receptor density, Bmax ~0.1 pmol\/mg protein) and human embroynic kidney (HEK)hUT (B max ~1.4 pmol\/mg protein) cells expressing native and recombinant UT, respectively. In SJCRH30, HEKhUT and human peripheral blood mononuclear cells induced to express native UT by treatment with 2 \u03bcg\/ml lipopolysaccharide (LPS), we have measured the effects of U-II treatment on UT mRNA. In SJCRH30 cells, primary stimulation with carbachol (250 \u03bcM) did not affect a secondary challenge with U-II (1 \u03bcM) and primary challenge with U-II did not affect a secondary challenge with carbachol. In contrast, in HEKhUT cells, primary stimulation with carbachol (250 \u03bcM) reduced a secondary challenge to U-II (1 \u03bcM) by 84% and primary challenge with U-II reduced a secondary challenge to carbachol by 76%. Pre-treatment of SJCRH30 cells with U-II reduced UT mRNA after 6 h and this returned to basal after 24 h. In recombinant HEKhUT cells, UT mRNA expression increased following a 6 h treatment with 1 \u03bcM U-II. U-II treatment of na\u00efve un-stimulated peripheral blood mononuclear cells was without effect. However, when UT expression is up-regulated following 15 h of LPS treatment, a 6 h U-II challenge reduced UT mRNA by 66%. In summary, we report differences in the desensitisation profiles of native and recombinant U-II receptors. Design and interpretation of functional experiments are hampered by irreversibility of U-II binding.<\/dc:description><dc:date>\n2010-05-13T11:46:42Z<\/dc:date><dc:date>\n2010-05-13T11:46:42Z<\/dc:date><dc:date>\n2009-08-13<\/dc:date><dc:type>\nArticle<\/dc:type><dc:identifier>\nNaunyn-Schmied Arch Pharmacol (2009) 380:451-457<\/dc:identifier><dc:identifier>\n0028-1298<\/dc:identifier><dc:identifier>\nhttp:\/\/link.springer.com\/article\/10.1007%2Fs00210-009-0441-9<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/2381\/7909<\/dc:identifier><dc:identifier>\n10.1007\/s00210-009-0441-9<\/dc:identifier><dc:language>\nen<\/dc:language><dc:format>\nMetadata<\/dc:format><dc:publisher>\nSpringer Verlag<\/dc:publisher>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":[{"title":null,"identifiers":["0028-1298","issn:0028-1298"]}],"language":null,"relations":[],"year":2009,"topics":["Calcium","Desensitisation","Peripheral blood mononuclear cells","Polymerase chain reaction","Urotensin II","Urotensin II receptor"],"subject":["Article"],"fullText":null}